UnknownNot applicableNCT06245876

Lung EpiCheck Biomarkers Development Study

This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.

Checked against the public recordLast updated Feb 12, 2024 · Source: ClinicalTrials.gov

StatusUnknown
PhaseNot applicable
U.S. locations10
SponsorNucleix Ltd.
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Nucleix Ltd.
Interventions being studied
Other: Blood collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria - Cases: * Age 50-80 years * Subjects who are currently smoking or former smokers, with at least 20 pack-years * Subjects with either A high suspicion for lung cancer, with planned biopsy or surgery to establish a definitive diagnosis within 60 days after enrollment or treatment naive lung cancer patients confirmed by pathology. Exclusion Criteria - Cases * Known diagnosis or treatment of cancer from any kind in the past 5 years, except of fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix and except from the current lung cancer Inclusion Criteria - USPSTF risk * Age 50-80 years * Subjects who are currently smoking or former smokers, with at least 20 pack-years Exclusion Criteria - USPSTF risk \- Known diagnosis or treatment of cancer of any kind in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix Inclusion Criteria - Healthy controls * Age 20-80 years * Never smoker or current / previous smoker \< 20 pack year history Exclusion Criteria - Healthy Controls * Known diagnosis or treatment of cancer of any kind in the past (lifetime), except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix. * Not previously diagnosed with a lung lesion highly suspicious for cancer * Under follow up or work up for any lesion suspicious for any type of cancer * Presenting with fever with body temperature 100.4°F (38°C) or higher * Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw * Pregnancy * Any history of blood product transfusion within 30 days prior to blood draw

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Life Spring Clinical ResearchMiami, Florida
  • Emerald Coast OBGYNPanama City, Florida
  • Ochsner LSU Health Shreveport - Regional UrologyShreveport, Louisiana
  • Comprehensive UrologySouthfield, Michigan
  • Michigan Institute of Urology, P.C.Troy, Michigan
  • Urology San AntonioSan Antonio, Texas
  • National Koranyi Institute for PulmonologyBudapest
  • Carmel Medical CenterHaifa
  • Sourasky Medical CenterTel Aviv
  • ZGT Medical CenterHengelo

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 12, 2024. Always confirm current availability with the study team.

View original record ↗